Welcome to Thursday's Overnight Health Care.

Today, Democrats jammed Republicans on drug pricing bills, Kevin McCarthy Kevin Owen McCarthyMcCarthy threatens motion to oust Pelosi if she moves forward with impeachment Kate Schroder in Ohio among Democratic challengers squelching GOP hopes for the House McCarthy's Democratic challenger to launch first TV ad highlighting Air Force service as single mother MORE said Alabama's abortion law goes too far, senators unveiled surprise medical bill legislation, and the administration backed off a controversial Medicare drug pricing change.

We'll start with the Democratic maneuvering on drug prices:

ADVERTISEMENT

Republicans cry foul over House Democrat tactics on drug pricing bills

House Democrats on Thursday forced Republicans to vote against their own drug pricing bills by packaging them with measures intended to shore up ObamaCare.

The House passed the package in a 234-183 vote, with Democrats drawing only five Republicans to vote with the majority.

As part of the package, Democrats voted on three bills that would help remove barriers to generic drugs entering the market and would crack down on tactics that lawmakers say pharmaceutical companies use to tamp down competition and keep prices high.

The bills were bipartisan and passed unanimously out of the Energy and Commerce Committee, but Democratic leaders this week combined them with legislation rolling back what they call the administration's "sabotage" of ObamaCare.

That forced Republicans into the tough position of voting down popular drug pricing bills, so as not to be seen as favoring ObamaCare.

ADVERTISEMENT

The move was slammed by Republicans for inserting politics into something that has traditionally been bipartisan.

"I have to express my regret that the bipartisan work we did ... gets paired up with a purely partisan bill they know we had problems with," said Rep. Greg Walden Gregory (Greg) Paul WaldenHillicon Valley: DOJ proposes tech liability shield reform to Congress | Treasury sanctions individuals, groups tied to Russian malign influence activities | House Republican introduces bill to set standards for self-driving cars OVERNIGHT ENERGY: California seeks to sell only electric cars by 2035 | EPA threatens to close New York City office after Trump threats to 'anarchist' cities | House energy package sparks criticism from left and right House energy package sparks criticism from left and right MORE (R-Ore.), the top Republican on the House Energy and Commerce Committee.

House Republican Leader Kevin McCarthy (R-Calif.) on Thursday decried what he called adding "partisan poison pills" to legislation where everyone was in agreement.

"They took a situation where we found common ground on drug pricing and transparency ... but before they came to the floor, they put poison pills in it dealing with the Affordable Care Act," McCarthy said.

We've got the full story here.

Fallout from Alabama's controversial abortion law... the House GOP leader is not on board

House Minority Leader Kevin McCarthy (R-Calif.) said Thursday he believes the Alabama law banning nearly all abortions goes too far.

"It goes further than I believe, yes," McCarthy said during a press conference.

McCarthy emphasized his opposition to abortion, saying, "First of all, I believe the most precious gift God gives us is life. And I [defended] my pro-life position my whole political career. "

But he added that he's always felt there should be exceptions -- such as for cases of rape, incest and the life of a woman being at risk -- when it comes to the law.

McCarthy's comments are a sign that even many Republicans are not comfortable with how far the Alabama law goes.

ADVERTISEMENT

Read more here.

And over in the upper chamber...

Senate GOP running away from Alabama abortion law

Senate Republicans are scrambling to distance themselves from a harsh new Alabama law that bans nearly all abortions, even in cases of rape and incest, and carries a penalty of up to 99 years in prison for anyone performing the procedure.

Most GOP senators are trying their best to steer clear of the firestorm, arguing it's a state-level issue that doesn't involve Congress. But the controversial law will undoubtedly stoke the abortion debate heading into the 2020 elections.

ADVERTISEMENT

Some of the reactions: Sen. Susan Collins Susan Margaret CollinsClub for Growth to spend million in ads for Trump Supreme Court nominee Maryland's GOP governor says Republicans shouldn't rush SCOTUS vote before election The Hill's Morning Report - Sponsored by Facebook - GOP closes ranks to fill SCOTUS vacancy by November MORE (Maine), who is up for reelection next year in a state Democratic presidential nominee Hillary Clinton Hillary Diane Rodham ClintonDemocratic groups using Bloomberg money to launch M in Spanish language ads in Florida The Hill's Campaign Report: Presidential polls tighten weeks out from Election Day More than 50 Latino faith leaders endorse Biden MORE won in 2016, is taking the lead in slamming the Alabama statute as "very extreme" and a "terrible law."

Sen. Lisa Murkowski Lisa Ann MurkowskiClub for Growth to spend million in ads for Trump Supreme Court nominee Pebble Mine CEO resigns over secretly recorded comments about government officials Maryland's GOP governor says Republicans shouldn't rush SCOTUS vote before election MORE (Alaska), another leading Republican moderate, declined to comment on the Alabama law as she headed into a lunch meeting Thursday.

When later pressed as she headed to the Senate floor for the final vote of the week, Murkowski told reporters that she disagrees with the lack of an exception for the victims of rape or incest.

"I think you know where I come from on that. I believe that there need to be exceptions," she said.

The Hill's Alex Bolton has more here.

Ocasio-Cortez confronts CEO for nearly $2K price tag on HIV drug that costs $8 in Australia

ADVERTISEMENT

Another moment from AOC that could go viral at a hearing today on the price of an HIV drug...

Rep. Alexandria Ocasio-Cortez Alexandria Ocasio-CortezWells Fargo CEO issues apology after saying there was a 'limited pool of Black talent' Brand responds to Trump claim protesters throw tuna cans at police: 'Eat em, don't throw em' CNN's Don Lemon: 'Blow up the entire system' remark taken out of context MORE (D-N.Y.) confronted a CEO Thursday for pricing a drug designed to reduce the risk of HIV transmission at $8 in Australia but over $1,500 in the U.S.

"You're the CEO of Gilead. Is it true that Gilead made $3 billion in profits from Truvada in 2018?" Ocasio-Cortez asked Gilead CEO Daniel O'Day.

"$3 billion in revenue," he clarified.

"The current list price is $2,000 a month in the United States, correct?" she asked, referring to Truvada.

"It's $1,780 in the United States," O'Day responded.

"Why is it $8 in Australia?" Ocasio-Cortez countered.

"Truvada still has patent protection in the United States and in the rest of the world it is generic," O'Day explained, adding, "It will be generically available in the United States as of September 2020."

Read more here.

SPONSORED CONTENT - CAMPAIGN FOR ACCOUNTABILITY

The Trump administration is quietly giving away millions of dollars intended for family planning services to a religious organization that refuses to provide contraception. Learn more.

Bipartisan senators unveil measure to end surprise medical bills

The action is picking up on stopping surprise medical bills.

The latest: Sens. Bill Cassidy William (Bill) Morgan CassidyCoushatta tribe begins long road to recovery after Hurricane Laura Senators offer disaster tax relief bill Bottom line MORE (R-La.), Maggie Hassan Margaret (Maggie) HassanDemocrats step up hardball tactics as Supreme Court fight heats up Congress needs to prioritize government digital service delivery Senate Democrats demand answers on migrant child trafficking during pandemic MORE (D-N.H.) and Michael Bennet Michael Farrand BennetOVERNIGHT ENERGY: House Democrats tee up vote on climate-focused energy bill next week | EPA reappoints controversial leader to air quality advisory committee | Coronavirus creates delay in Pentagon research for alternative to 'forever chemicals' Senate Democrats demand White House fire controversial head of public lands agency Next crisis, keep people working and give them raises MORE (D-Colo.) led a group of senators on Thursday introducing a bill.

Bipartisan momentum: Hassan, a Democrat, noted that she joined Trump at the White House for an event last week to call for an end to surprise bills.

"There is strong bipartisan momentum behind ending the absurd practice of surprise medical bills," she said. "Sen. Cassidy and I were at the White House last week to join the president as he spoke out on the importance of addressing this issue."

What to watch: Sens. Lamar Alexander Andrew (Lamar) Lamar AlexanderGraham: GOP has votes to confirm Trump's Supreme Court nominee before the election The Hill's Morning Report - Sponsored by Facebook - Washington on edge amid SCOTUS vacancy This week: Supreme Court fight over Ginsburg's seat upends Congress's agenda MORE (R-Tenn.) and Patty Murray Patricia (Patty) Lynn MurraySenate Democrats introduce legislation to probe politicization of pandemic response Trump health officials grilled over reports of politics in COVID-19 response CDC director pushes back on Caputo claim of 'resistance unit' at agency MORE (D-Wash.) are still working on their own plan. That will be key to watch given that Alexander is the chairman of the relevant panel, and their bill is set to be included in a broader package to lower health care costs that Alexander hopes will come to the Senate floor this summer.

Read more here.

Trump administration backs off controversial Medicare drug pricing rule

The Trump administration on Thursday backed off a controversial Medicare drug pricing proposal that would have allowed insurers to exclude certain drugs if prices rise faster than inflation.

In a final rule, the administration said it was leaving in place the current policy about Medicare's "protected classes" of drugs.

Under current law, private Medicare health plans are required to cover all or "substantially all" drugs in six "protected" classes, such as HIV treatments, antidepressants, drugs to prevent blood clots, and cancer drugs, regardless of cost.

Last fall, the administration proposed allowing health plans to exclude protected drugs with price increases that are greater than inflation, as well as certain new drug formulations that were not a "significant innovation" over the original product.

The move, which was aimed at lowering drug costs for private Medicare plans, was vigorously opposed by some patient advocacy groups, which argued the plan would have decreased seniors' access to medicine.

This isn't the first time an administration has tried to save money by cutting the protected classes. In 2014, then-President Obama tried to remove the protected status from some types of drugs, but he also backed off after outrage from patient groups and bipartisan lawmakers.

Read more on the rule here.

What we're reading

In Washington, a partisan approach to lowering drug costs leaves Democrats doubting their own party leadership (Stat News)

How generic drug makers are responding to price-fixing lawsuit (PBS Newshour)

The costliest drug on the planet will treat infants with rare disease. The market fight focused on cost and safety is just getting started. (The Washington Post)

Opioid crisis has spread beyond United States: OECD (Reuters)

State by state

Alabama just enacted the country's most restrictive abortion law. What happens now? (CNN.com)

'The time is now': States are rushing to restrict abortion, or to protect it (The New York Times)

From The Hill's opinion page:

Private equity is a driving force behind devious surprise billing

Abortion ban: There's nothing sweet about Alabama